{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:46:00Z","timestamp":1776260760429,"version":"3.50.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The real-world status of proton pump inhibitor (PPI) administration in patients with acute coronary syndrome (ACS) and atrial fibrillation (AF) remains largely unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to analyze the prescription pattern, trends and influencing factors of PPIs among Chinese patients with ACS and AF at discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective, cross-sectional study included patients with ACS and AF who were hospitalized at the Cardiovascular Center of Beijing Tongren Hospital from January 2010 to December 2018. All patients were subsequently categorized into two groups based on PPI administration at discharge (i.e., the PPI and non-PPI group), after which factors influencing PPI use were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      This study included 531 patients diagnosed with ACS and AF, with a median age of 73 years, 61.4% of these patients were male. Among them, 254 patients (47.8%) were administered PPIs. A significant increasing trend in PPI administration was observed from 21.3% (2010\u20132012) to 63.5% (2016\u20132018) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). Patients receiving PPIs were more likely to have non-ST-segment elevation myocardial infarction (UNSTEMI) [adjusted odds ratio (OR) 3.358, 95% confidence interval (CI) 1.819\u20136.196,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001], ST-elevation myocardial infarction (STEMI) [adjusted OR 4.092, 95% CI 2.177\u20137.694,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001], paroxysmal AF [adjusted OR 1.732, 95% CI 1.022\u20132.936,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.041], GI disorders [adjusted OR 17.625, 95% CI 9.783\u201331.751,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001], were more likely to undergo catheter ablation [adjusted OR 13.368, 95% CI 3.836\u201346.586,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001] and more likely to receive oral anticoagulants [adjusted OR 1.918, 95% CI 1.006\u20133.658,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.048] compared to those not receiving PPIs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings revealed that approximately 50% of patients with AF and ACS were prescribed PPI at discharge, highlighting the need to carefully evaluate the risks and benefits of combining antithrombotic medications and PPIs on an individual basis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1601616","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:49:01Z","timestamp":1776257341000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Current status of proton pump inhibitor usage in patients with acute coronary syndrome and atrial fibrillation: a cross-sectional study"],"prefix":"10.3389","volume":"13","author":[{"given":"Ying","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Center, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1056\/NEJMe1902214","article-title":"Refining antithrombotic therapy for atrial fibrillation and acute coronary syndromes or PCI","volume":"380","author":"Mehta","year":"2019","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e002053","DOI":"10.1161\/CIRCINTERVENTIONS.114.002053","article-title":"Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions","volume":"8","author":"Koskinas","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"18020","DOI":"10.1038\/nrdp.2018.20","article-title":"Non-variceal upper gastrointestinal bleeding","volume":"4","author":"Lanas","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1097\/MEG.0000000000001125","article-title":"Reduction in post percutaneous coronary intervention angina in addition to gastrointestinal events in patients on combined proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis","volume":"30","author":"Khan","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European heart rhythm association (EHRA), European society of cardiology working group on thrombosis, European association of percutaneous cardiovascular interventions (EAPCI), and European association of acute cardiac care (ACCA) endorsed by the heart rhythm society (HRS), Asia-Pacific heart rhythm society (APHRS), Latin America heart rhythm society (LAHRS), and cardiac arrhythmia society of Southern Africa (CASSA)","volume":"21","author":"Lip","year":"2019","journal-title":"EP Europace"},{"key":"B14","first-page":"1775","article-title":"Expert consensus on the preventive application of proton pump inhibitors (2018)","volume":"20","year":"2018","journal-title":"Journal of Chinese Physician"},{"key":"B15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.14309\/ajg.0000000000001134","article-title":"Trials of dual antiplatelet therapy after percutaneous coronary intervention lack strategies to ensure appropriate gastroprotection","volume":"116","author":"Kurlander","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"115502","DOI":"10.1016\/j.bone.2020.115502","article-title":"Association between proton pump inhibitors use and risk of hip fracture: a general population-based cohort study","volume":"139","author":"Wei","year":"2020","journal-title":"Bone"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1007\/s11255-018-1908-8","article-title":"The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis","volume":"50","author":"Sun","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/pds.1715","article-title":"Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid suppressants: a population-based case-control study","volume":"18","author":"Myles","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.3748\/wjg.v25.i33.4933","article-title":"Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis","volume":"25","author":"Roza","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3748\/wjg.v25.i21.2675","article-title":"Proton pump inhibitor use increases hepatic encephalopathy risk: a systematic review and meta-analysis","volume":"25","author":"Ma","year":"2019","journal-title":"World J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1038\/s41467-024-48007-8","article-title":"Individualized prevention of proton pump inhibitor related adverse events by risk stratification","volume":"15","author":"Xia","year":"2024","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1586\/17512433.2013.811206","article-title":"Perils and pitfalls of long-term effects of proton pump inhibitors","volume":"6","author":"Wilhelm","year":"2013","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.14309\/ajg.0000000000001809","article-title":"Proton pump inhibitors and risk of cardiovascular disease: a self-controlled case series study","volume":"117","author":"Park","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/apt.16407","article-title":"Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors","volume":"54","author":"Salvo","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1093\/eurheartj\/ehz104","article-title":"Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction","volume":"40","author":"Sehested","year":"2019","journal-title":"Eur Heart J"},{"key":"B27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.mayocp.2021.11.037","article-title":"Proton pump inhibitors and in-hospital gastrointestinal bleeding in patients with acute coronary syndrome receiving dual antiplatelet therapy","volume":"97","author":"Zhou","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0240859","DOI":"10.1371\/journal.pone.0240859","article-title":"Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: a subanalysis of the ANAFIE registry","volume":"15","author":"Mizokami","year":"2020","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"923684","DOI":"10.3389\/fcvm.2022.923684","article-title":"Efficacy and safety of antithrombotic therapy with oral anticoagulants in real-world elderly patients with acute coronary syndrome and atrial fibrillation","volume":"9","author":"Wu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.cgh.2017.04.031","article-title":"Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis","volume":"15","author":"Miller","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1053\/j.gastro.2016.12.018","article-title":"Gastrointestinal safety of direct oral anticoagulants: a large population-based study","volume":"152","author":"Abraham","year":"2017","journal-title":"Gastroenterology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.cgh.2016.12.033","article-title":"Gastrointestinal bleeding with oral anticoagulation: understanding the scope of the problem","volume":"15","author":"Vaduganathan","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1160\/TH13-02-0150","article-title":"Gastrointestinal bleeding with the new oral anticoagulants\u2013defining the issues and the management strategies","volume":"110","author":"Desai","year":"2013","journal-title":"Thromb Haemost"},{"key":"B34","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2147\/CLEP.S219335","article-title":"Differences in gastrointestinal safety profiles among novel oral anticoagulants: evidence from A network meta-analysis","volume":"11","author":"Guo","year":"2019","journal-title":"Clin Epidemiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e007956","DOI":"10.1161\/CIRCEP.121.007956","article-title":"Drug interactions affecting oral anticoagulant use","volume":"15","author":"Mar","year":"2022","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"769251","DOI":"10.3389\/fphar.2021.769251","article-title":"Fatal adverse events of dabigatran combined with aspirin in elderly patients: an analysis using data from VigiBase","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/cpt.2369","article-title":"Association between use of pharmacokinetic-interacting drugs and effectiveness and safety of direct acting oral anticoagulants: nested case-control study","volume":"110","author":"Gronich","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"969259","DOI":"10.3389\/fcvm.2022.969259","article-title":"Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants-A nationwide cohort study","volume":"9","author":"Wu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.amjmed.2014.01.044","article-title":"Serious bleeding events due to warfarin and antibiotic co-prescription in a cohort of veterans","volume":"127","author":"Lane","year":"2014","journal-title":"Am J Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/jamia\/ocab019","article-title":"DDIWAS: high-throughput electronic health record-based screening of drug-drug interactions","volume":"28","author":"Wu","year":"2021","journal-title":"J Am Med Inform Assoc"},{"key":"B41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-9560-12-20","article-title":"Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study","volume":"12","author":"Teklay","year":"2014","journal-title":"Thromb J"},{"key":"B42","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12959-021-00353-z","article-title":"Changes of antithrombotic prescription in atrial fibrillation patients with acute coronary syndrome or percutaneous coronary intervention and the subsequent impact on long-term outcomes: a longitudinal cohort study","volume":"19","author":"Lee","year":"2021","journal-title":"Thromb J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamacardio.2019.1880","article-title":"Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials","volume":"4","author":"Lopes","year":"2019","journal-title":"JAMA Cardiol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4497","DOI":"10.1093\/eurheartj\/ehaa617","article-title":"Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial","volume":"41","author":"Vranckx","year":"2020","journal-title":"Eur Heart J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jjcc.2023.03.004","article-title":"Antithrombotic therapies in Canadian atrial fibrillation patients with concomitant coronary artery disease: insights from the CONNECT AF\u202f+\u202fPCI-II program","volume":"82","author":"Chow","year":"2023","journal-title":"J Cardiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e05879","DOI":"10.1002\/ccr3.5879","article-title":"A rare case of pediatric pancreatic pseudocyst","volume":"10","author":"Jaiswal","year":"2022","journal-title":"Clin Case Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ajg.2025.02.003","article-title":"A novel nomogram for predicting the risk of coronary atherosclerosis in patients with gastroesophageal reflux disease","volume":"26","author":"Wu","year":"2025","journal-title":"Arab J Gastroenterol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1601616\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:49:02Z","timestamp":1776257342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1601616\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":48,"alternative-id":["10.3389\/fcvm.2026.1601616"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1601616","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1601616"}}